Mid-Time period Plan
FYE March 2024 to FYE March 2028
|
Date of Launch |
：Could 10, 2023 |
|
Monetary Outcomes Briefing |
：Could 11, 2023 |
Japan Lifeline Co., Ltd.
TSE Prime Market /Ticker Image 7575
Unauthorized copying prohibited.
Copyright © 2023 Japan Lifeline Co., Ltd. All rights reserved.
- We remodeled the enterprise previously 1-2 years, which concerned reviewing the portfolio:
-
- Phased down the coronary intervention enterprise*1, together with early termination of the drug- eluting coronary stent “Orsiro”.
- Terminated unique gross sales of “RF Needle,” one of many important merchandise.
- Divested blood purification enterprise, which had low synergy with different companies.
- Concentrated sources on new areas (neurovascular & gastrointestinal) and current areas of power (EP/ablation and cardiovascular).
- To replicate the most recent state of affairs, we now have withdrawn the present plan and established a brand new plan.
Present Mid-Time period Plan
|
FYE March 2021~2025 |
Renewal |
Introduced in Nov 2020
New Mid-Time period Plan
FYE March 2024~2028
Introduced in Could 2023
*1 Coronary Intervention falls beneath the “PI-related” subcategory within the “Gastrointestinal/PI” gross sales class for FYE March 2023.
Agenda
|
1. |
Enterprise Overview |
|
|
マ |
2. |
Administration Philosophy |
|
ー |
||
|
ジ |
3. |
Mid-Time period Steerage |
|
ン |
||
|
指 |
||
|
定 |
4. |
Capital Technique |
|
2 |
||
|
. |
||
|
0 |
||
|
cm |
5. |
Sustainability |
マ
ー
ジ
ン
指
定
2 . 0 cm
Agenda
|
1. |
Enterprise Overview |
|
|
マ |
2. |
Administration Philosophy |
|
ー |
||
|
ジ |
3. |
Mid-Time period Steerage |
|
ン |
||
|
指 |
||
|
定 |
4. |
Capital Technique |
|
2 |
||
|
. |
||
|
0 |
||
|
cm |
5. |
Sustainability |
マ
ー
ジ
ン
指
定
2 . 0 cm
Our Monitor File
- Japan Lifeline has grown based mostly on a novel manufacturing and distribution enterprise mannequin and by providing one-of-a-kindin-house merchandise.
|
FYE March 2023 |
|||||
|
¥bln |
Internet Gross sales |
||||
|
60 |
Internet Gross sales-In-house |
¥51.7bln |
|||
|
マ |
50 |
Internet Gross sales-Third Social gathering |
マ |
||
|
TSE 1st Part |
|||||
|
ー |
ー |
||||
|
ジ |
Launched Open Stent Graft Frozenix |
ジ |
|||
|
ン |
40 |
Cardiovascular one-of-a-kind product |
FYE March 2023 |
ン |
|
|
指 |
Launched Inside Atrial |
In-house gross sales ratio |
指 |
||
|
54.9% |
|||||
|
定 |
30 |
Began creating in-house merchandise |
Cardioversion Catheter BeeAT |
定 |
|
|
2 |
EP/Ablation one-of-a-kind product |
2 |
|||
|
. |
. |
||||
|
0 |
0 |
||||
|
cm |
20 |
JASDAQ (OTC listed) |
cm |
||
|
10 |
|||||
|
0 |
|||||
|
マージン指定1.5cm |
5 |
Disclaimer
JLL – Japan Lifeline Co. Ltd. printed this content material on 10 Could 2023 and is solely answerable for the knowledge contained therein. Distributed by Public, unedited and unaltered, on 10 Could 2023 12:40:10 UTC.
Publicnow 2023
|
|
|
|
|
|
|
||||
|
||||
Technical evaluation tendencies JAPAN LIFELINE CO., LTD.
| Brief Time period | Mid-Time period | Lengthy Time period | |
| Tendencies | Impartial | Impartial | Impartial |
Earnings Assertion Evolution
|
Promote  Purchase |
|
| Imply consensus | OUTPERFORM |
| Variety of Analysts | 4 |
| Final Shut Value | 950,00 JPY |
| Common goal worth | 1 035,00 JPY |
| Unfold / Common Goal | 8,95% |